Relationgship of genetic polymorphisms of ERCC1 with the clinical prognosis to platin-based chemotherapy in patients with advanced non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2013.08.006
- VernacularTitle:核苷酸切除修复交叉互补组基因1单核苷酸多态性与晚期非小细胞肺癌患者铂类药物化疗预后的关系
- Author:
Guoren ZHOU
;
Jinjun YE
;
Jifeng FENG
;
Jianwei LU
;
Chunlian JIANG
- Publication Type:Journal Article
- Keywords:
Polymorphism,single nucleotide;
Genotype;
Carcinoma,non-small-cell lung;
Platinbased combined chemotherapy;
Survival period
- From:
Cancer Research and Clinic
2013;25(8):523-526
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between genetic polymorphisms of ERCC1 and survival rate in advanced non-small cell lung cancer (NSCLC) patients treated with platinum based chemotherapy.Methods A total of 204 patients with advanced NSCLC were routinely treated by platinbased chemotherapy.The polymorphic genotypes were analyzed by MALDI-TOF-MS nethod using DNA samples isolated from peripheral blood before treatment.Besides,5 ％ samples werc extracted randomly for sequencing to test the accuracy of this method.To explored the association between SNP of ERCC1 (118) and prognosis to platinum-based chemotherapy in advanced NSCLC patients.Results Among 204 patients,61 achieved partial response,116 achieved stable response,and 27 achieved progressive disease.The overall response rate was 29.9 ％ (61/204).The effective rates of patients with the ERCC1 (118) C/C genotype,C/T + T/T genotype were 24.0 ％ (29/121) and 38.6 ％ (32/83),respectively,with significant difference (P ＜ 0.05).The response rate of ERCC1 (118) C/T allele carriers was 1.992-fold than that of C/C allele carriers (95 ％ confidence interval:1.083-3.650,P =0.025).MST,1-year survival and 2-year survival rates of patients with the ERCC1 (118) C/C genotype,C/T + T/T genotype were 9.0 months,34.7 ％ (42/121) and 4.1％ (5/121) vs 12.0 months,60.2 ％ (50/83) and 12.0 ％ (10/83),respectively,with significant difference (P ＜ 0.05).Conclusions Polymorphisms of ERCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy,which might be the predictive markers for overall survival.
